Physician profile
Thomas Schrepfer
NPI 1093168668
$4,007.59
in general payments reported to CMS, 2019-2025
11 companies · $2,293 in 2025
The $2,293 reported for 2025 was more than what 92% of Pediatric Otolaryngology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $875 · 2022: $429 · 2024: $116 · 2025: $2,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,071 · Food and Beverage: $237 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,071.00 |
| Food and Beverage | $237.42 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $2,946.00 | 2020-2025 | N.A. |
| Cochlear Americas | $223.28 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $158.36 | 2024-2025 | Dupixent |
| Smith+Nephew, INC. | $146.07 | 2022 | |
| Med-El Corporation | $121.42 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Alk-Abello, INC | $93.99 | 2019 | |
| Stryker Corporation | $78.37 | 2022 | |
| Cook Medical LLC | $61.09 | 2019 | |
| Genzyme Corporation | $48.00 | 2024 | |
| 3-D Matrix, INC. | $31.06 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Schrepfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.